Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The 4S study and its pharmacoeconomic implications.

× No keyword cloud information.

19 in total

1. Should there be a moratorium on the use of cholesterol lowering drugs?

Authors: G Davey Smith; J Pekkanen
Journal: BMJ Date: 1992-02-15

2. Cost implications of lipid-lowering treatments.

Authors: J P Reckless
Journal: Pharmacoeconomics Date: 1994-10 Impact factor: 4.981

3. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands.

Authors: L L Martens; F F Rutten; D W Erkelens; C A Ascoop
Journal: Am J Cardiol Date: 1990-03-20 Impact factor: 2.778

4. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs.

Authors: D K Wysowski; T P Gross
Journal: Arch Intern Med Date: 1990-10

5. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors: G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal: N Engl J Med Date: 1990-11-08 Impact factor: 91.245

6. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

Authors: M R Law; N J Wald; S G Thompson
Journal: BMJ Date: 1994-02-05

7. Assessing possible hazards of reducing serum cholesterol.

Authors: M R Law; S G Thompson; N J Wald
Journal: BMJ Date: 1994-02-05

8. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.

Authors: L Goldman; M C Weinstein; P A Goldman; L W Williams
Journal: JAMA Date: 1991-03-06 Impact factor: 56.272

9. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).

Authors: B Pitt; S G Ellis; G B Mancini; H S Rosman; M E McGovern
Journal: Am J Cardiol Date: 1993-07-01 Impact factor: 2.778

10. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245

6 in total

1. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

Authors: D M Pickin; C J McCabe; L E Ramsay; N Payne; I U Haq; W W Yeo; P R Jackson
Journal: Heart Date: 1999-09 Impact factor: 5.994

Review 2. Resource utilisation in the management of dyslipidaemia.

Authors: T D Szucs
Journal: Pharmacoeconomics Date: 1998 Impact factor: 4.981

3. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.

Authors: M J Koren; D G Smith; D B Hunninghake; M H Davidson; J M McKenney; S R Weiss; H G Schrott; R W Henley; P Tresh; R W McLain; R G Bakker-Arkema; D M Black
Journal: Pharmacoeconomics Date: 1998-07 Impact factor: 4.981

The 4S study and its pharmacoeconomic implications.